Abstract
The positive role of G-CSF in hastening the myeloid recovery of patients undergoing allogeneic bone marrow transplantation (ALLO-BMT) or autologous bone marrow transplantation (ABMT) has recently been established. Considerable knowledge about adequate doses and route of administration has been accumulated in the past few years. Nonetheless, the optimal time to start growth-factor administration remains undetermined. We have performed a stratified study according to the source of hematopoietic progenitors (ALLO-BMT or ABMT), underlying disease and its stage, and acute graft-versus-host disease (GVHD) prophylaxis regimen and randomized patients in two arms: group A, which started G-CSF on day 0 (36 patients), and group B, which started on day +7 post-BMT (39 patients). The same dose (5 Μg/kg/day) and route of administration were employed in both groups. We found no significant differences in the time to reach an absolute neutrophil count (ANC) of 0.1, 0.5, and 1×109/l and 50×109 platelets/l (medians: 10 and 11, 14.5 and 14, 17 and 16, 23 and 24 days, respectively, in groups A and B). We did not find differences in the days of fever or days on antibiotic treatment with less than 1×109/l ANC, rate of bacteriemia, or days of hospitalization in both groups. In contrast, a considerable saving of GCSF in B group was found (mean days of infusion in group A, 18, versus 11 in group B) (p<0.0001). This is equivalent to a saving of 1120 $US per patient. Therefore, early use of G-CSF after BMT is useless and more expensive and provides no advantage over delayed administration.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Brandt SJ, Peters WP, Atwater SK, Kurtzberg J, Borowitz MJ, Jones RB, Shpall EJ, Gilbert CJ, Bast RC Jr, Oette DH (1988) Effect of recombinant human granulocyte-macrophage colony-stimulating factor on hemopoietic reconstitution after high-dose chemotherapy and autologous bone marrow transplantation. N Engl J Med 318:869–876
Crawford J, Ozer H, Stollen R, Johnson D, Lyman G, Tabbara I, Kris M, Groos J, Picozzi V, Rauch G, Smith R, Gradishar W, Yahanda A, Vicent M, Stewart M, Glaspy J (1991) Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 325:164–170
Ganser A, Lindemann A, Seipelt G, Ottmann OG, Herrman F, Eder M, Frisch J, Schultz G, Merstelsmann R, Hoelzer D (1989) Effect of recombinant human interleukin-3 (rhIL-3) in patients with bone marrow failure. A phase I/II trial. Blood 74 [Suppl. 1]:50a (abstract 177)
Haas R, Genicke G, Witt B, Cayeux S, Hunstein W (1993) Increased serum levels of granulocyte colony-stimulating factor alter autologous bone marrow or blood stem cell transplantation. Exp Hematol 21:109–113
Ikebuchi K, Ihle JN, Hirai Y, Wong GG, Clark SC, Ogawa M (1988) Synergistic factors for stem cell proliferation: further studies of the target stem cells and the mechanism of stimulation by IL-1, IL-6 and G-CSF. Blood 72:2007–2014
Khwaja A, Yong K, Jones HM, Chopra R, McMillan AK, Goldstone AH, Patterson KG, Matheson C, Ruthuen K, Abrahmson SB, Linch DC (1992) The effect of macrophage colony-stimulating factor on hemopoietic recovery after autologous bone marrow transplantation. Br J Haematol 81:288–295
Khwaja A, Mills W, Leveridge AH, Goldstone AH, Linch DC (1993) Efficacy of delayed granulocyte colony-stimulating factor after autologous BMT. Bone Marrow Transplant 11:479–482
Linch DC, Scarffe H, Proctor S, Chopra R, Taylor PRA, Morgenstern G, Cunnigham D, Burnett AK, Cawley JC, Franklin JM, Bell AJ, Lister TA, Marcus RE, Newland AC, Parker AC, Yver A (1993) A randomized vehicle-controlled dose-finding study of glycosylated recombinant human granulocyte colony-stimulating factor after bone marrow transplantation. Bone Marrow Transplant 11:307–311
Masaoka T, Takaku F, Kato S, Moriyama Y, Kodera Y, Kanamaru A, Shimosaka A, Shibata H, Nakamura H (1989) Recombinant human granulocyte colony-stimulating factor in allogeneic bone marrow transplantation. Exp Hematol 17:1047–1050
Mertelsmann R (1991) Hematopoietins: biology, pathophysiology and potential as therapeutic agent. Annals of Oncology 2:251–263
Metcalf D (1990) The colony-stimulating factors: discovery, development and clinical applications. Cancer 65:2185–2195
Metcalf D (1991) Control of granulocytes and macrophages: molecular, cellular and clinical aspects. Science 254:529–533
Nemunaitis J, Singer JW, Buckner CD, Hill R, Storb R, Thomas ED, Appelbaum F (1988) The use of rHuGM-CSF for graft failure in patients after autologous, allogeneic or syngeneic bone marrow transplantation (BMT). Blood 72 [suppl 1]:398A (abstract 1503)
Nemunaitis J, Rabinowe SN, Singer JW, Bierman PJ, Vose JM, Freedman AS, Onetto N, Gillis S, Oette D, Gold M, Buckner CD, Hansen JA, Ritz J, Appelbaum FR, Armitage JO, Nadler LM (1991) Recombinant granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid cancer. N Engl J Med 324:1773–1778
Peters WP (1991) The myeloid colony-stimulating factors: introduction and overview. Semin Hematol 28:1–5
Rabinowe SN, Nemunaitis J, Armitage J, Nadler LM (1991) The impact of myeloid growth factors on engraftment following autologous bone marrow transplantation for malignant lymphoma. Semin Hematol 28:6–16
Sheridan WP, Morstyn G, Wolf M, Dodds A, Lusk J, Maher D, Layton J, Green M, Souza L, Fox R (1989) Granulocyte colony-stimulating factor and neutrophil recovery after highdose chemotherapy and autologous bone marrow transplantation. Lancet 2:891–895
Souza LM, Boone TC, Gabrilove J, Lai PH, Zsebo KM, Murdock DC, Chazin VR, Bruszewski J, Lu H, Chen KK, Barendt J, Platzer E, Moore MAS, Mertelsmann R, Welte K (1986) Recombinant human granulocyte colony-stimulating factor effects on normal and leukemic myeloid cells. Science 232:61–65
Taylor KM, Jagannath S, Spitzer G, Spinolo JA, Tucker SL, Fogel B, Cabanillas FF, Hagemeister FB, Souza LM (1989) Recombinant human granulocyte colony-stimulating factor hastens granulocyte recovery after high-dose chemotherapy and autologous bone marrow transplantation in Hodgkin's disease. J Clin Oncol 7:1791–1799
Teshima H, Ishikawa J, Kitayama H, Yamagani T, Hiraoka A, Nakamura H, Shibata H, Masaoka T, Takaku F (1989) Clinical effects of recombinant human granulocyte colonystimulating factor in leukemia patients: a phase I/II study. Exp Hematol 17:853–858
Torres A, Martinez F, Gomez P, Herrera C, Rojas R, GomezVillagran JL, Garcia-Castellano JM, Velasco F, Andres P, Fornes G, Manzanares R (1989) Cyclosporin A versus methotrexate followed by rescue with folinic acid as prophylaxis of acute graft versus host disease after bone marrow transplantation. Blut 58:63–68
Vey N, Blaise D, Molnar S, Nouyrigat P, Novakovitch G, Viens P, Stoppa AM, Bouahdallah R, Mannoni P, Maraninchi D (1994) Impact of G-CSF post auto BMT: no versus D1 versus D6 on 88 patients. 20th Annual Meeting of the European Group for Bone Marrow Transplantation, Harrogate, England. Bone Marrow Transplant 106: (Abstract 46)
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Gómez, A.T., Jimenez, M.A., Alvarez, M.A. et al. Optimal timing of granulocyte colony-stimulating factor (G-CSF) administration after bone marrow transplantation. Ann Hematol 71, 65–70 (1995). https://doi.org/10.1007/BF01699248
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01699248